Thus, it is possible that the pathways dysregulated by RPL22 insufficiency in patients with MDS or AML may be less profoundly impacted or distinct from those perturbed in mice by Rpl22 deficiency. This evidence concerns the gene RPL22 and acute myeloid leukemia.